Pharmaceutical

Super DC Vaccine by Shanghai Cell Therapy Group for Solid Tumor: Likelihood of Approval

Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor.

Oct 3, 2023 - 20:00
Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor.
Read the original article

Tags:

Previous Article

Nitric oxide by NOxy Health Products for Diabetic Foot Ulcers: Likelihood of App...

Next Article

MC-232 by MC2 Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Eli Lilly and Innovent’s obesity drug mazdutide achieves positive Phase III results

Eli Lilly and Innovent’s obesity drug mazdutide achieve...

Jan 11, 2024

STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial

STAT+: Pfizer to halt development of its twice-daily or...

Dec 1, 2023

FDA grants approval for Pfizer’s RSV vaccine

FDA grants approval for Pfizer’s RSV vaccine

Aug 22, 2023